Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218


Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.

Park D, Magis AT, Li R, Owonikoko TK, Sica GL, Sun SY, Ramalingam SS, Khuri FR, Curran WJ, Deng X.

Cancer Res. 2013 Sep 1;73(17):5485-96. doi: 10.1158/0008-5472.CAN-12-2272. Epub 2013 Jul 3.


Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.

Rooswinkel RW, van de Kooij B, Verheij M, Borst J.

Cell Death Dis. 2012 Aug 9;3:e366. doi: 10.1038/cddis.2012.109.


'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, Fesik SW, Shen Y.

Oncogene. 2007 Jun 7;26(27):3972-9. Epub 2006 Dec 18.


Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.

Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, Kmieciak M, Reshko LB, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Grant S.

Haematologica. 2015 Dec;100(12):1553-63. doi: 10.3324/haematol.2015.130351. Epub 2015 Oct 9.


ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL.

Li JY, Li YY, Jin W, Yang Q, Shao ZM, Tian XS.

J Exp Clin Cancer Res. 2012 Dec 23;31:102. doi: 10.1186/1756-9966-31-102.


Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.

Yamaguchi R, Janssen E, Perkins G, Ellisman M, Kitada S, Reed JC.

PLoS One. 2011;6(9):e24102. doi: 10.1371/journal.pone.0024102. Epub 2011 Sep 19.


Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.

Okumura K, Huang S, Sinicrope FA.

Clin Cancer Res. 2008 Dec 15;14(24):8132-42. doi: 10.1158/1078-0432.CCR-08-1665.


γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.

Séveno C, Loussouarn D, Bréchet S, Campone M, Juin P, Barillé-Nion S.

Breast Cancer Res. 2012 Jun 15;14(3):R96.


The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.

Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N.

Hepatology. 2010 Oct;52(4):1310-21. doi: 10.1002/hep.23836.


Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.

Sun JG, Xiang J, Zeng XL, Li X, Wu P, Fung KP, Liu FY.

Cancer Lett. 2014 Dec 28;355(2):253-63. doi: 10.1016/j.canlet.2014.09.024. Epub 2014 Oct 7.


BH3-only protein bid participates in the Bcl-2 network in healthy liver cells.

Hikita H, Takehara T, Kodama T, Shimizu S, Hosui A, Miyagi T, Tatsumi T, Ishida H, Ohkawa K, Li W, Kanto T, Hiramatsu N, Hennighausen L, Yin XM, Hayashi N.

Hepatology. 2009 Dec;50(6):1972-80. doi: 10.1002/hep.23207.


Drp1 is dispensable for apoptotic cytochrome c release in primed MCF10A and fibroblast cells but affects Bcl-2 antagonist-induced respiratory changes.

Clerc P, Ge SX, Hwang H, Waddell J, Roelofs BA, Karbowski M, Sesaki H, Polster BM.

Br J Pharmacol. 2014 Apr;171(8):1988-99. doi: 10.1111/bph.12515.


Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages.

Kodama T, Hikita H, Kawaguchi T, Shigekawa M, Shimizu S, Hayashi Y, Li W, Miyagi T, Hosui A, Tatsumi T, Kanto T, Hiramatsu N, Kiyomizu K, Tadokoro S, Tomiyama Y, Hayashi N, Takehara T.

Cell Death Differ. 2012 Nov;19(11):1856-69. doi: 10.1038/cdd.2012.88. Epub 2012 Jul 13.


Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.

Hari Y, Harashima N, Tajima Y, Harada M.

Oncotarget. 2015 Dec 8;6(39):41902-15. doi: 10.18632/oncotarget.5881.


Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak.

Lindqvist LM, Heinlein M, Huang DC, Vaux DL.

Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8512-7. doi: 10.1073/pnas.1406425111. Epub 2014 May 27.


Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.

Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP.

Blood. 2015 Jul 16;126(3):363-72. doi: 10.1182/blood-2014-10-604975. Epub 2015 Jun 4.


BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.

Morii T, Ohtsuka K, Ohnishi H, Mochizuki K, Yoshiyama A, Aoyagi T, Hornicek FJ, Ichimura S.

Anticancer Res. 2014 Nov;34(11):6423-30.


The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.

Cao X, Yap JL, Newell-Rogers MK, Peddaboina C, Jiang W, Papaconstantinou HT, Jupitor D, Rai A, Jung KY, Tubin RP, Yu W, Vanommeslaeghe K, Wilder PT, MacKerell AD Jr, Fletcher S, Smythe RW.

Mol Cancer. 2013 May 16;12(1):42. doi: 10.1186/1476-4598-12-42.


Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer.

Zeuner A, Francescangeli F, Contavalli P, Zapparelli G, Apuzzo T, Eramo A, Baiocchi M, De Angelis ML, Biffoni M, Sette G, Todaro M, Stassi G, De Maria R.

Cell Death Differ. 2014 Dec;21(12):1877-88. doi: 10.1038/cdd.2014.105. Epub 2014 Jul 18.

Supplemental Content

Support Center